{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:38:27Z","timestamp":1778182707766,"version":"3.51.4"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10497-z","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T10:29:18Z","timestamp":1740047358000},"page":"715-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Worsening heart failure: progress, pitfalls, and perspectives"],"prefix":"10.1007","volume":"30","author":[{"given":"C\u00e2ndida","family":"Fonseca","sequence":"first","affiliation":[]},{"given":"Rui","family":"Baptista","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Franco","sequence":"additional","affiliation":[]},{"given":"Brenda","family":"Moura","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Pimenta","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Moraes Sarmento","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Silva","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Dulce","family":"Brito","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"10497_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","volume":"73","author":"J Butler","year":"2019","unstructured":"Butler J, Yang M, Manzi MA et al (2019) Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol 73:935\u2013944. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.049","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR2","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH et al (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118:3272\u20133287. https:\/\/doi.org\/10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"10497_CR3","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, Abate D, Abate KH et al (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789\u20131858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet"},{"key":"10497_CR4","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","volume":"29","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Ahmad T, Alexander KM et al (2023) Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail 29:1412\u20131451. https:\/\/doi.org\/10.1016\/j.cardfail.2023.07.006","journal-title":"J Card Fail"},{"key":"10497_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW (2020) Epidemiology of heart failure. Eur J Heart Fail 22:1342\u20131356. https:\/\/doi.org\/10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"key":"10497_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1388-9842(02)00034-X","volume":"4","author":"F Ceia","year":"2002","unstructured":"Ceia F, Fonseca C, Mota T et al (2002) Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 4:531\u2013539. https:\/\/doi.org\/10.1016\/S1388-9842(02)00034-X","journal-title":"Eur J Heart Fail"},{"key":"10497_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.repc.2017.11.010","volume":"37","author":"C Fonseca","year":"2018","unstructured":"Fonseca C, Br\u00e1s D, Ara\u00fajo I, Ceia F (2018) Insufici\u00eancia card\u00edaca em n\u00fameros: estimativas para o s\u00e9culo XXI em Portugal. Rev Port Cardiol 37:97\u2013104. https:\/\/doi.org\/10.1016\/j.repc.2017.11.010","journal-title":"Rev Port Cardiol"},{"key":"10497_CR8","unstructured":"Baptista R et al (2024) PORTHOS - Portuguese Heart Failure Prevalence Observational Study. In: Heart Failure 2024. p Saturday, 11 May-Tuesday, 14 May 2024 Lisbon-P"},{"key":"10497_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.repc.2023.10.004","volume":"42","author":"R Baptista","year":"2023","unstructured":"Baptista R, Silva Cardoso J, Canh\u00e3o H et al (2023) Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design \u2013 A population-based study. Rev Port Cardiol 42:985\u2013995. https:\/\/doi.org\/10.1016\/j.repc.2023.10.004","journal-title":"Rev Port Cardiol"},{"key":"10497_CR10","doi-asserted-by":"publisher","unstructured":"Gouveia MR de A, Ascen\u00e7\u00e3o RMS e S, Fiorentino F, et al (2020) Os custos da insufici\u00eancia card\u00edaca em Portugal e a sua evolu\u00e7\u00e3o previs\u00edvel com o envelhecimento da popula\u00e7\u00e3o. Rev Port Cardiol 39:3\u201311. https:\/\/doi.org\/10.1016\/j.repc.2019.09.006","DOI":"10.1016\/j.repc.2019.09.006"},{"key":"10497_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ehf2.12399","volume":"6","author":"M Gouveia","year":"2019","unstructured":"Gouveia M, Ascen\u00e7\u00e3o R, Fiorentino F et al (2019) The current and future burden of heart failure in Portugal. ESC Hear Fail 6:254\u2013261. https:\/\/doi.org\/10.1002\/ehf2.12399","journal-title":"ESC Hear Fail"},{"key":"10497_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10741-021-10097-7","volume":"27","author":"H Clark","year":"2022","unstructured":"Clark H, Rana R, Gow J et al (2022) Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review. Heart Fail Rev 27:559\u2013572. https:\/\/doi.org\/10.1007\/s10741-021-10097-7","journal-title":"Heart Fail Rev"},{"key":"10497_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.21037\/cdt-20-291","volume":"11","author":"FP Hessel","year":"2021","unstructured":"Hessel FP (2021) Overview of the socio-economic consequences of heart failure. Cardiovasc Diagn Ther 11:254\u2013262. https:\/\/doi.org\/10.21037\/cdt-20-291","journal-title":"Cardiovasc Diagn Ther"},{"key":"10497_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.18553\/jmcp.2022.28.2.157","volume":"28","author":"KM Osenenko","year":"2022","unstructured":"Osenenko KM, Kuti E, Deighton AM et al (2022) Burden of hospitalization for heart failure in the United States: a systematic literature review. J Manag Care Spec Pharm 28:157\u2013167. https:\/\/doi.org\/10.18553\/jmcp.2022.28.2.157","journal-title":"J Manag Care Spec Pharm"},{"key":"10497_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","volume":"143","author":"I Johansson","year":"2021","unstructured":"Johansson I, Joseph P, Balasubramanian K et al (2021) Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries. Circulation 143:2129\u20132142. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050850","journal-title":"Circulation"},{"key":"10497_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11886-021-01588-y","volume":"23","author":"KE Freedland","year":"2021","unstructured":"Freedland KE, Rich MW, Carney RM (2021) Improving quality of life in heart failure. Curr Cardiol Rep 23:159. https:\/\/doi.org\/10.1007\/s11886-021-01588-y","journal-title":"Curr Cardiol Rep"},{"key":"10497_CR17","doi-asserted-by":"publisher","first-page":"e0283146","DOI":"10.1371\/journal.pone.0283146","volume":"18","author":"H Mulugeta","year":"2023","unstructured":"Mulugeta H, Sinclair PM, Wilson A (2023) Prevalence of depression and its association with health-related quality of life in people with heart failure in low- and middle-income countries: a systematic review and meta-analysis. PLoS ONE 18:e0283146. https:\/\/doi.org\/10.1371\/journal.pone.0283146","journal-title":"PLoS ONE"},{"key":"10497_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ejhf.1996","volume":"23","author":"CJ Taylor","year":"2021","unstructured":"Taylor CJ, Ord\u00f3\u00f1ez-Mena JM, Jones NR et al (2021) National trends in heart failure mortality in men and women, United Kingdom, 2000\u20132017. Eur J Heart Fail 23:3\u201312. https:\/\/doi.org\/10.1002\/ejhf.1996","journal-title":"Eur J Heart Fail"},{"key":"10497_CR19","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","volume":"19","author":"AS Koh","year":"2017","unstructured":"Koh AS, Tay WT, Teng THK et al (2017) A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 19:1624\u20131634. https:\/\/doi.org\/10.1002\/ejhf.945","journal-title":"Eur J Heart Fail"},{"key":"10497_CR20","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1002\/ehf2.13921","volume":"9","author":"S Chen","year":"2022","unstructured":"Chen S, Huang Z, Liang Y et al (2022) Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort. ESC Hear Fail 9:2336\u20132347. https:\/\/doi.org\/10.1002\/ehf2.13921","journal-title":"ESC Hear Fail"},{"key":"10497_CR21","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA et al (2017) Heart failure with preserved, borderline, and reduced ejection fraction. J Am Coll Cardiol 70:2476\u20132486. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.074","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jacasi.2022.11.013","volume":"3","author":"T Nagata","year":"2023","unstructured":"Nagata T, Ide T, Tohyama T et al (2023) Long-term outcomes of heart failure patients with preserved, mildly reduced, and reduced ejection fraction. JACC Asia 3:315\u2013316. https:\/\/doi.org\/10.1016\/j.jacasi.2022.11.013","journal-title":"JACC Asia"},{"key":"10497_CR23","doi-asserted-by":"publisher","first-page":"e007132","DOI":"10.1161\/CIRCHEARTFAILURE.120.007132","volume":"13","author":"SJ Greene","year":"2020","unstructured":"Greene SJ, Fonarow GC, Butler J (2020) Risk profiles in heart failure: baseline, residual, worsening, and advanced heart failure risk. Circ Heart Fail 13:e007132. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007132","journal-title":"Circ Heart Fail"},{"key":"10497_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","volume":"12","author":"SJ Greene","year":"2015","unstructured":"Greene SJ, Fonarow GC, Vaduganathan M et al (2015) The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 12:220\u2013229. https:\/\/doi.org\/10.1038\/nrcardio.2015.14","journal-title":"Nat Rev Cardiol"},{"key":"10497_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jama.2014.6643","volume":"312","author":"J Butler","year":"2014","unstructured":"Butler J, Braunwald E, Gheorghiade M (2014) Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA 312:789. https:\/\/doi.org\/10.1001\/jama.2014.6643","journal-title":"JAMA"},{"key":"10497_CR26","doi-asserted-by":"publisher","unstructured":"Metra M, Tomasoni D, Adamo M, et al (2023) Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the heart failure association of the European society of cardiology. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.2874","DOI":"10.1002\/ejhf.2874"},{"key":"10497_CR27","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 145. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"key":"10497_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14354","author":"A Shakoor","year":"2023","unstructured":"Shakoor A, Emans ME, van Gent MWF et al (2023) Regional management of worsening heart failure: rationale and design of the CHAIN-HF registry. ESC Hear Fail. https:\/\/doi.org\/10.1002\/ehf2.14354","journal-title":"ESC Hear Fail"},{"key":"10497_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamacardio.2017.5250","volume":"3","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Mentz RJ, Felker GM (2018) Outpatient worsening heart failure as a target for therapy. JAMA Cardiol 3:252. https:\/\/doi.org\/10.1001\/jamacardio.2017.5250","journal-title":"JAMA Cardiol"},{"key":"10497_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","volume":"81","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ et al (2023) Worsening heart failure: nomenclature, epidemiology, and future directions. J Am Coll Cardiol 81:413\u2013424. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.023","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2023.04.057","volume":"82","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ et al (2023) Management of worsening heart failure with reduced ejection fraction. J Am Coll Cardiol 82:559\u2013571. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.057","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejim.2019.10.017","volume":"71","author":"M Kobayashi","year":"2020","unstructured":"Kobayashi M, Voors AA, Girerd N et al (2020) Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. Eur J Intern Med 71:62\u201369. https:\/\/doi.org\/10.1016\/j.ejim.2019.10.017","journal-title":"Eur J Intern Med"},{"key":"10497_CR33","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/ejhf.2276","volume":"23","author":"M Pagnesi","year":"2021","unstructured":"Pagnesi M, Adamo M, Sama IE et al (2021) Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. Eur J Heart Fail 23:1750\u20131758. https:\/\/doi.org\/10.1002\/ejhf.2276","journal-title":"Eur J Heart Fail"},{"key":"10497_CR34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/ejhf.2431","volume":"24","author":"J Tromp","year":"2022","unstructured":"Tromp J, Beusekamp JC, Ouwerkerk W et al (2022) Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry. Eur J Heart Fail 24:645\u2013652. https:\/\/doi.org\/10.1002\/ejhf.2431","journal-title":"Eur J Heart Fail"},{"key":"10497_CR35","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/ejhf.1796","volume":"22","author":"CJ Kapelios","year":"2020","unstructured":"Kapelios CJ, Laroche C, Crespo-Leiro MG et al (2020) Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 22:1424\u20131437. https:\/\/doi.org\/10.1002\/ejhf.1796","journal-title":"Eur J Heart Fail"},{"key":"10497_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD et al (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38:1883\u20131890. https:\/\/doi.org\/10.1093\/eurheartj\/ehx026","journal-title":"Eur Heart J"},{"key":"10497_CR37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jacc.2013.10.017","volume":"63","author":"T Thorvaldsen","year":"2014","unstructured":"Thorvaldsen T, Benson L, St\u00e5hlberg M et al (2014) Triage of patients with moderate to severe heart failure. J Am Coll Cardiol 63:661\u2013671. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.017","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ejhf.71","volume":"16","author":"H Skali","year":"2014","unstructured":"Skali H, Dwyer EM, Goldstein R et al (2014) Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail 16:560\u2013565. https:\/\/doi.org\/10.1002\/ejhf.71","journal-title":"Eur J Heart Fail"},{"key":"10497_CR39","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","volume":"133","author":"N Okumura","year":"2016","unstructured":"Okumura N, Jhund PS, Gong J et al (2016) Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Circulation 133:2254\u20132262. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020729","journal-title":"Circulation"},{"key":"10497_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jacc.2022.04.045","volume":"80","author":"AP Ambrosy","year":"2022","unstructured":"Ambrosy AP, Parikh RV, Sung SH et al (2022) Analysis of worsening heart failure events in an integrated health care system. J Am Coll Cardiol 80:111\u2013122. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.045","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR41","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/ejhf.1800","volume":"22","author":"JH Butt","year":"2020","unstructured":"Butt JH, Fosb\u00f8l EL, Gerds TA et al (2020) Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. Eur J Heart Fail 22:1777\u20131785. https:\/\/doi.org\/10.1002\/ejhf.1800","journal-title":"Eur J Heart Fail"},{"key":"10497_CR42","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","volume":"142","author":"KF Docherty","year":"2020","unstructured":"Docherty KF, Jhund PS, Anand I et al (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction. Circulation 142:1623\u20131632. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047480","journal-title":"Circulation"},{"key":"10497_CR43","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jacc.2020.12.026","volume":"77","author":"SJ Greene","year":"2021","unstructured":"Greene SJ, Triana TS, Ionescu-Ittu R et al (2021) Patients hospitalized for De Novo versus worsening chronic heart failure in the United States. J Am Coll Cardiol 77:1023\u20131025. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.026","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR44","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","volume":"133","author":"N Okumura","year":"2016","unstructured":"Okumura N, Jhund PS, Gong J et al (2016) Importance of clinical worsening of heart failure treated in the outpatient setting. Circulation 133:2254\u20132262. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020729","journal-title":"Circulation"},{"key":"10497_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2015.06.017","volume":"4","author":"LF Buckley","year":"2016","unstructured":"Buckley LF, Carter DM, Matta L et al (2016) Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Hear Fail 4:1\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2015.06.017","journal-title":"JACC Hear Fail"},{"key":"10497_CR46","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.cardfail.2019.10.015","volume":"26","author":"LF Buckley","year":"2020","unstructured":"Buckley LF, Stevenson LW, Cooper IM et al (2020) Ambulatory treatment of worsening heart failure with intravenous loop diuretics: a four-year experience. J Card Fail 26:798\u2013799. https:\/\/doi.org\/10.1016\/j.cardfail.2019.10.015","journal-title":"J Card Fail"},{"key":"10497_CR47","doi-asserted-by":"publisher","unstructured":"Khan MS, Greene SJ, Hellkamp AS, et al (2021) Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the change the management of patients with heart failure registry. Circ Hear Fail 14. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008351","DOI":"10.1161\/CIRCHEARTFAILURE.121.008351"},{"key":"10497_CR48","doi-asserted-by":"publisher","unstructured":"Madelaire C, Gustafsson F, Stevenson LW, et al (2020) One\u2010year mortality after intensification of outpatient diuretic therapy. J Am Heart Assoc 9. https:\/\/doi.org\/10.1161\/JAHA.119.016010","DOI":"10.1161\/JAHA.119.016010"},{"key":"10497_CR49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ejhf.1323","volume":"21","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Metra M, Mordi I et al (2019) Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. Eur J Heart Fail 21:112\u2013120. https:\/\/doi.org\/10.1002\/ejhf.1323","journal-title":"Eur J Heart Fail"},{"key":"10497_CR50","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","volume":"6","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Giczewska A, Sliwa K et al (2021) Clinical outcomes and response to vericiguat according to index heart failure event. JAMA Cardiol 6:706. https:\/\/doi.org\/10.1001\/jamacardio.2020.6455","journal-title":"JAMA Cardiol"},{"key":"10497_CR51","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jchf.2021.01.014","volume":"9","author":"M Vaduganathan","year":"2021","unstructured":"Vaduganathan M, Cunningham JW, Claggett BL et al (2021) Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction. JACC Hear Fail 9:374\u2013382. https:\/\/doi.org\/10.1016\/j.jchf.2021.01.014","journal-title":"JACC Hear Fail"},{"key":"10497_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M et al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 24:4\u2013131. https:\/\/doi.org\/10.1002\/ejhf.2333","journal-title":"Eur J Heart Fail"},{"key":"10497_CR53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCHEARTFAILURE.112.000161","volume":"6","author":"L Tavazzi","year":"2013","unstructured":"Tavazzi L, Senni M, Metra M et al (2013) Multicenter prospective observational study on acute and chronic heart failure. Circ Hear Fail 6:473\u2013481. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000161","journal-title":"Circ Hear Fail"},{"key":"10497_CR54","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35611","author":"H In\u00e1cio","year":"2023","unstructured":"In\u00e1cio H, De Carvalho A, Gamelas De Carvalho J et al (2023) Real-life data on readmissions of worsening heart failure outpatients in a heart failure clinic. Cureus. https:\/\/doi.org\/10.7759\/cureus.35611","journal-title":"Cureus"},{"key":"10497_CR55","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1016\/j.jacc.2017.04.043","volume":"69","author":"SJ Greene","year":"2017","unstructured":"Greene SJ, Hernandez AF, Dunning A et al (2017) Hospitalization for recently diagnosed versus worsening chronic heart failure. J Am Coll Cardiol 69:3029\u20133039. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.043","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR56","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cardfail.2021.05.017","volume":"27","author":"SB Dunbar","year":"2021","unstructured":"Dunbar SB, Tan X, Lautsch D et al (2021) Patient-centered outcomes in HFrEF following a worsening heart failure event: a survey analysis. J Card Fail 27:877\u2013887. https:\/\/doi.org\/10.1016\/j.cardfail.2021.05.017","journal-title":"J Card Fail"},{"key":"10497_CR57","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jchf.2023.06.001","volume":"11","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B (2023) Differentiation between worsening heart failure and decompensated heart failure. JACC Hear Fail 11:859\u2013861. https:\/\/doi.org\/10.1016\/j.jchf.2023.06.001","journal-title":"JACC Hear Fail"},{"key":"10497_CR58","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ejhf.2503","volume":"24","author":"N Girerd","year":"2022","unstructured":"Girerd N, Mewton N, Tarti\u00e8re J et al (2022) Practical outpatient management of worsening chronic heart failure. Eur J Heart Fail 24:750\u2013761. https:\/\/doi.org\/10.1002\/ejhf.2503","journal-title":"Eur J Heart Fail"},{"key":"10497_CR59","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/ejhf.1050","volume":"20","author":"LNL Van Aelst","year":"2018","unstructured":"Van Aelst LNL, Arrigo M, Placido R et al (2018) Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail 20:738\u2013747. https:\/\/doi.org\/10.1002\/ejhf.1050","journal-title":"Eur J Heart Fail"},{"key":"10497_CR60","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.108.783910","volume":"118","author":"MR Zile","year":"2008","unstructured":"Zile MR, Bennett TD, St John Sutton M et al (2008) Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 118:1433\u20131441. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.783910","journal-title":"Circulation"},{"key":"10497_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrcardio.2015.134","volume":"13","author":"RJ Mentz","year":"2016","unstructured":"Mentz RJ, O\u2019Connor CM (2016) Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol 13:28\u201335. https:\/\/doi.org\/10.1038\/nrcardio.2015.134","journal-title":"Nat Rev Cardiol"},{"key":"10497_CR62","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.pcad.2020.04.007","volume":"63","author":"D Tomasoni","year":"2020","unstructured":"Tomasoni D, Lombardi CM, Sbolli M et al (2020) Acute heart failure: More questions than answers. Prog Cardiovasc Dis 63:599\u2013606. https:\/\/doi.org\/10.1016\/j.pcad.2020.04.007","journal-title":"Prog Cardiovasc Dis"},{"key":"10497_CR63","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.1989.03420060100040","volume":"261","author":"LW Stevenson","year":"1989","unstructured":"Stevenson LW, Perloff JK (1989) The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261:884\u2013888","journal-title":"JAMA"},{"key":"10497_CR64","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jchf.2017.09.023","volume":"6","author":"N Girerd","year":"2018","unstructured":"Girerd N, Seronde M-F, Coiro S et al (2018) Integrative assessment of congestion in heart failure throughout the patient journey. JACC Hear Fail 6:273\u2013285. https:\/\/doi.org\/10.1016\/j.jchf.2017.09.023","journal-title":"JACC Hear Fail"},{"key":"10497_CR65","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.jacc.2019.01.072","volume":"73","author":"MG Del Buono","year":"2019","unstructured":"Del Buono MG, Arena R, Borlaug BA et al (2019) Exercise intolerance in patients with heart failure. J Am Coll Cardiol 73:2209\u20132225. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.072","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ejhf.2778","volume":"25","author":"G Savarese","year":"2023","unstructured":"Savarese G, Lindenfeld J, Stolfo D et al (2023) Use of patient-reported outcomes in heart failure: from clinical trials to routine practice. Eur J Heart Fail 25:139\u2013151. https:\/\/doi.org\/10.1002\/ejhf.2778","journal-title":"Eur J Heart Fail"},{"key":"10497_CR67","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jchf.2022.03.003","volume":"10","author":"J Butler","year":"2022","unstructured":"Butler J, Shahzeb Khan M, Lindenfeld J et al (2022) Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF. JACC Hear Fail 10:651\u2013661. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.003","journal-title":"JACC Hear Fail"},{"key":"10497_CR68","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM et al (2022) 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618\u20133731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237","journal-title":"Eur Heart J"},{"key":"10497_CR69","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/ejhf.2346","volume":"23","author":"WC Meijers","year":"2021","unstructured":"Meijers WC, Bayes-Genis A, Mebazaa A et al (2021) Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail 23:1610\u20131632. https:\/\/doi.org\/10.1002\/ejhf.2346","journal-title":"Eur J Heart Fail"},{"key":"10497_CR70","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","volume":"21","author":"C Mueller","year":"2019","unstructured":"Mueller C, McDonald K, de Boer RA et al (2019) Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 21:715\u2013731. https:\/\/doi.org\/10.1002\/ejhf.1494","journal-title":"Eur J Heart Fail"},{"key":"10497_CR71","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ejhf.2664","volume":"24","author":"J N\u00fa\u00f1ez","year":"2022","unstructured":"N\u00fa\u00f1ez J, de la Espriella R, Rossignol P et al (2022) Congestion in heart failure: a circulating biomarker-based perspective. A review from the biomarkers working group of the heart failure association, european society of cardiology. Eur J Heart Fail 24:1751\u20131766. https:\/\/doi.org\/10.1002\/ejhf.2664","journal-title":"Eur J Heart Fail"},{"key":"10497_CR72","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1093\/eurheartj\/ehab579","volume":"42","author":"SJ Pocock","year":"2021","unstructured":"Pocock SJ, Ferreira JP, Gregson J et al (2021) Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. Eur Heart J 42:4455\u20134464. https:\/\/doi.org\/10.1093\/eurheartj\/ehab579","journal-title":"Eur Heart J"},{"key":"10497_CR73","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ejhf.1019","volume":"20","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Fonarow GC et al (2018) Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail 20:281\u2013291. https:\/\/doi.org\/10.1002\/ejhf.1019","journal-title":"Eur J Heart Fail"},{"key":"10497_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12872-016-0221-7","volume":"16","author":"P Karlstr\u00f6m","year":"2016","unstructured":"Karlstr\u00f6m P, Johansson P, Dahlstr\u00f6m U et al (2016) Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study. BMC Cardiovasc Disord 16:39. https:\/\/doi.org\/10.1186\/s12872-016-0221-7","journal-title":"BMC Cardiovasc Disord"},{"key":"10497_CR75","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ejhf.287","volume":"17","author":"J \u00c1lvarez-Garc\u00eda","year":"2015","unstructured":"\u00c1lvarez-Garc\u00eda J, Ferrero-Gregori A, Puig T et al (2015) A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCORE. Eur J Heart Fail 17:818\u2013827. https:\/\/doi.org\/10.1002\/ejhf.287","journal-title":"Eur J Heart Fail"},{"key":"10497_CR76","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/ejhf.2352","volume":"23","author":"P Codina","year":"2021","unstructured":"Codina P, Lup\u00f3n J, Borrellas A et al (2021) Head-to-head comparison of contemporary heart failure risk scores. Eur J Heart Fail 23:2035\u20132044. https:\/\/doi.org\/10.1002\/ejhf.2352","journal-title":"Eur J Heart Fail"},{"key":"10497_CR77","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","volume":"387","author":"WT Abraham","year":"2016","unstructured":"Abraham WT, Stevenson LW, Bourge RC et al (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387:453\u2013461. https:\/\/doi.org\/10.1016\/S0140-6736(15)00723-0","journal-title":"Lancet"},{"key":"10497_CR78","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","volume":"377","author":"WT Abraham","year":"2011","unstructured":"Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658\u2013666. https:\/\/doi.org\/10.1016\/S0140-6736(11)60101-3","journal-title":"Lancet"},{"key":"10497_CR79","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/heartjnl-2022-321885","volume":"109","author":"JP Curtain","year":"2023","unstructured":"Curtain JP, Lee MMY, McMurray JJ et al (2023) Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart 109:823\u2013831. https:\/\/doi.org\/10.1136\/heartjnl-2022-321885","journal-title":"Heart"},{"key":"10497_CR80","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1093\/eurheartj\/ehad280","volume":"44","author":"NTB Scholte","year":"2023","unstructured":"Scholte NTB, G\u00fcrg\u00f6ze MT, Aydin D et al (2023) Telemonitoring for heart failure: a meta-analysis. Eur Heart J 44:2911\u20132926. https:\/\/doi.org\/10.1093\/eurheartj\/ehad280","journal-title":"Eur Heart J"},{"key":"10497_CR81","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1002\/ehf2.12999","volume":"7","author":"A Nunes-Ferreira","year":"2020","unstructured":"Nunes-Ferreira A, Agostinho JR, Rigueira J et al (2020) Non-invasive telemonitoring improves outcomes in heart failure with reduced ejection fraction: a study in high-risk patients. ESC Hear Fail 7:3996\u20134004. https:\/\/doi.org\/10.1002\/ehf2.12999","journal-title":"ESC Hear Fail"},{"key":"10497_CR82","doi-asserted-by":"publisher","first-page":"86","DOI":"10.15420\/cfr.2019.5.3","volume":"5","author":"DH Brahmbhatt","year":"2019","unstructured":"Brahmbhatt DH, Cowie MR (2019) Remote management of heart failure: an overview of telemonitoring technologies. Card Fail Rev 5:86\u201392. https:\/\/doi.org\/10.15420\/cfr.2019.5.3","journal-title":"Card Fail Rev"},{"key":"10497_CR83","doi-asserted-by":"publisher","unstructured":"Brito D (2021) Remote monitoring of heart failure patients: a complex proximity. Rev Port Cardiol (English Ed 40:353\u2013356. https:\/\/doi.org\/10.1016\/j.repce.2021.06.003","DOI":"10.1016\/j.repce.2021.06.003"},{"key":"10497_CR84","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10741-019-09801-5","volume":"25","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Gu X, Xu C (2020) Effectiveness of telemedicine systems for adults with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev 25:231\u2013243. https:\/\/doi.org\/10.1007\/s10741-019-09801-5","journal-title":"Heart Fail Rev"},{"key":"10497_CR85","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"10497_CR86","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cardfail.2018.08.011","volume":"24","author":"MG Dickinson","year":"2018","unstructured":"Dickinson MG, Allen LA, Albert NA et al (2018) remote monitoring of patients with heart failure: a white paper from the heart failure society of America scientific statements committee. J Card Fail 24:682\u2013694. https:\/\/doi.org\/10.1016\/j.cardfail.2018.08.011","journal-title":"J Card Fail"},{"key":"10497_CR87","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.repc.2019.03.006","volume":"38","author":"JR Agostinho","year":"2019","unstructured":"Agostinho JR, Gon\u00e7alves I, Rigueira J et al (2019) Protocol-based follow-up program for heart failure patients: Impact on prognosis and quality of life. Rev Port Cardiol 38:755\u2013764. https:\/\/doi.org\/10.1016\/j.repc.2019.03.006","journal-title":"Rev Port Cardiol"},{"key":"10497_CR88","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/ehf2.13949","volume":"10","author":"T Rodrigues","year":"2023","unstructured":"Rodrigues T, Agostinho JR, Santos R et al (2023) The value of multiparametric prediction scores in heart failure varies with the type of follow-up after discharge: a comparative analysis. ESC Hear Fail 10:2550\u20132558. https:\/\/doi.org\/10.1002\/ehf2.13949","journal-title":"ESC Hear Fail"},{"key":"10497_CR89","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/ejhf.2032","volume":"23","author":"P Pellicori","year":"2021","unstructured":"Pellicori P, Platz E, Dauw J et al (2021) Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur J Heart Fail 23:703\u2013712. https:\/\/doi.org\/10.1002\/ejhf.2032","journal-title":"Eur J Heart Fail"},{"key":"10497_CR90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13089-021-00232-8","volume":"13","author":"P Rola","year":"2021","unstructured":"Rola P, Miralles-Aguiar F, Argaiz E et al (2021) Clinical applications of the venous excess ultrasound (VExUS) score: conceptual review and case series. Ultrasound J 13:32. https:\/\/doi.org\/10.1186\/s13089-021-00232-8","journal-title":"Ultrasound J"},{"key":"10497_CR91","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Am Coll Cardiol 79:e263\u2013e421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR92","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485. https:\/\/doi.org\/10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"key":"10497_CR93","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jchf.2015.11.011","volume":"4","author":"MR Costanzo","year":"2016","unstructured":"Costanzo MR, Stevenson LW, Adamson PB et al (2016) Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC Hear Fail 4:333\u2013344. https:\/\/doi.org\/10.1016\/j.jchf.2015.11.011","journal-title":"JACC Hear Fail"},{"key":"10497_CR94","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1540-8159.2008.02245.x","volume":"32","author":"D Catanzariti","year":"2009","unstructured":"Catanzariti D, Lunati M, Landolina M et al (2009) Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. Pacing Clin Electrophysiol 32:363\u2013370. https:\/\/doi.org\/10.1111\/j.1540-8159.2008.02245.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"10497_CR95","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ejhf.2025","volume":"23","author":"J Koehler","year":"2021","unstructured":"Koehler J, Stengel A, Hofmann T et al (2021) Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study. Eur J Heart Fail 23:186\u2013194. https:\/\/doi.org\/10.1002\/ejhf.2025","journal-title":"Eur J Heart Fail"},{"key":"10497_CR96","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/ejhf.1906","volume":"22","author":"M Galinier","year":"2020","unstructured":"Galinier M, Roubille F, Berdague P et al (2020) Telemonitoring versus standard care in heart failure: a randomised multicentre trial. Eur J Heart Fail 22:985\u2013994. https:\/\/doi.org\/10.1002\/ejhf.1906","journal-title":"Eur J Heart Fail"},{"key":"10497_CR97","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s11886-023-01907-5","volume":"25","author":"M Olson","year":"2023","unstructured":"Olson M, Thompson Z, Xie L, Nair A (2023) Broadening heart failure care beyond cardiology: challenges and successes within the landscape of multidisciplinary heart failure care. Curr Cardiol Rep 25:851\u2013861. https:\/\/doi.org\/10.1007\/s11886-023-01907-5","journal-title":"Curr Cardiol Rep"},{"key":"10497_CR98","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cardfail.2020.10.008","volume":"27","author":"SJ Greene","year":"2021","unstructured":"Greene SJ, Adusumalli S, Albert NM et al (2021) Building a heart failure clinic: a practical guide from the heart failure society of America. J Card Fail 27:2\u201319. https:\/\/doi.org\/10.1016\/j.cardfail.2020.10.008","journal-title":"J Card Fail"},{"key":"10497_CR99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","volume":"32","author":"G Sayer","year":"2014","unstructured":"Sayer G, Bhat G (2014) The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin 32:21\u201332. https:\/\/doi.org\/10.1016\/j.ccl.2013.09.002","journal-title":"Cardiol Clin"},{"key":"10497_CR100","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.repc.2018.10.008","volume":"38","author":"C Fonseca","year":"2019","unstructured":"Fonseca C, Brito D, Ferreira J et al (2019) Sacubitril\/valsartan: A practical guide. Rev Port Cardiol 38:309\u2013313. https:\/\/doi.org\/10.1016\/j.repc.2018.10.008","journal-title":"Rev Port Cardiol"},{"key":"10497_CR101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.amjms.2016.06.016","volume":"353","author":"S Antoine","year":"2017","unstructured":"Antoine S, Vaidya G, Imam H, Villarreal D (2017) Pathophysiologic mechanisms in heart failure: role of the sympathetic nervous system. Am J Med Sci 353:27\u201330. https:\/\/doi.org\/10.1016\/j.amjms.2016.06.016","journal-title":"Am J Med Sci"},{"key":"10497_CR102","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ejhf.799","volume":"19","author":"E D\u2019Elia","year":"2017","unstructured":"D\u2019Elia E, Iacovoni A, Vaduganathan M et al (2017) Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 19:710\u2013717. https:\/\/doi.org\/10.1002\/ejhf.799","journal-title":"Eur J Heart Fail"},{"key":"10497_CR103","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2174\/1574887109666140908125402","volume":"9","author":"S Prijic","year":"2014","unstructured":"Prijic S, Buchhorn R (2014) Mechanisms of beta-blockers action in patients with heart failure. Rev Recent Clin Trials 9:58\u201360. https:\/\/doi.org\/10.2174\/1574887109666140908125402","journal-title":"Rev Recent Clin Trials"},{"key":"10497_CR104","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers SA, Brown NJ (2016) Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 133:1115\u20131124. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018622","journal-title":"Circulation"},{"key":"10497_CR105","doi-asserted-by":"publisher","first-page":"60","DOI":"10.14740\/cr1221","volume":"12","author":"B Nightingale","year":"2021","unstructured":"Nightingale B (2021) A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure. Cardiol Res 12:60\u201366. https:\/\/doi.org\/10.14740\/cr1221","journal-title":"Cardiol Res"},{"key":"10497_CR106","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","volume":"143","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Packer M (2021) How should we sequence the treatments for heart failure and a reduced ejection fraction? Circulation 143:875\u2013877. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052926","journal-title":"Circulation"},{"key":"10497_CR107","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"10497_CR108","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"10497_CR109","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"10497_CR110","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"10497_CR111","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad344","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan M, Mentz RJ, Claggett BL et al (2023) Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehad344","journal-title":"Eur Heart J"},{"key":"10497_CR112","doi-asserted-by":"publisher","first-page":"106931","DOI":"10.1016\/j.phrs.2023.106931","volume":"196","author":"R Mollace","year":"2023","unstructured":"Mollace R, Scarano F, Bava I et al (2023) Modulation of the nitric oxide\/cGMP pathway in cardiac contraction and relaxation: Potential role in heart failure treatment. Pharmacol Res 196:106931. https:\/\/doi.org\/10.1016\/j.phrs.2023.106931","journal-title":"Pharmacol Res"},{"key":"10497_CR113","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","volume":"76","author":"M Emdin","year":"2020","unstructured":"Emdin M, Aimo A, Castiglione V et al (2020) Targeting cyclic guanosine monophosphate to treat heart failure. J Am Coll Cardiol 76:1795\u20131807. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.031","journal-title":"J Am Coll Cardiol"},{"key":"10497_CR114","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10741-019-09881-3","volume":"25","author":"C Zuchi","year":"2020","unstructured":"Zuchi C, Tritto I, Carluccio E et al (2020) Role of endothelial dysfunction in heart failure. Heart Fail Rev 25:21\u201330. https:\/\/doi.org\/10.1007\/s10741-019-09881-3","journal-title":"Heart Fail Rev"},{"key":"10497_CR115","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15698","author":"P Sandner","year":"2021","unstructured":"Sandner P, Follmann M, Becker-Pelster E et al (2021) Soluble GC stimulators and activators: past, present and future. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.15698","journal-title":"Br J Pharmacol"},{"key":"10497_CR116","doi-asserted-by":"publisher","unstructured":"Sandner P, Zimmer DP, Milne GT, et al (2018) Soluble guanylate cyclase stimulators and activators. pp 355\u2013394. https:\/\/doi.org\/10.1007\/164_2018_197","DOI":"10.1007\/164_2018_197"},{"key":"10497_CR117","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J et al (2015) Effect of Vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction. JAMA 314:2251. https:\/\/doi.org\/10.1001\/jama.2015.15734","journal-title":"JAMA"},{"key":"10497_CR118","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883\u20131893. https:\/\/doi.org\/10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"10497_CR119","doi-asserted-by":"publisher","first-page":"L20","DOI":"10.1093\/eurheartjsupp\/suac124","volume":"24","author":"D Tomasoni","year":"2022","unstructured":"Tomasoni D, Adamo M, Bozkurt B et al (2022) Aiming at harmony. Comparing and contrasting International HFrEF Guidelines. Eur Hear J Suppl 24:L20\u2013L28. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac124","journal-title":"Eur Hear J Suppl"},{"key":"10497_CR120","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.cardfail.2022.10.431","volume":"29","author":"VN Rao","year":"2023","unstructured":"Rao VN, Diez J, Gustafsson F et al (2023) Practical patient care considerations with use of vericiguat after worsening heart failure events. J Card Fail 29:389\u2013402. https:\/\/doi.org\/10.1016\/j.cardfail.2022.10.431","journal-title":"J Card Fail"},{"key":"10497_CR121","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400:1938\u20131952. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1","journal-title":"Lancet"},{"key":"10497_CR122","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384:117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"10497_CR123","doi-asserted-by":"publisher","unstructured":"Psotka MA, Teerlink JR (2017) Direct myosin activation by omecamtiv mecarbil for heart failure with reduced ejection fraction. pp 465\u2013490.\u00a0https:\/\/doi.org\/10.1007\/164_2017_13","DOI":"10.1007\/164_2017_13"},{"key":"10497_CR124","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM et al (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 384:105\u2013116. https:\/\/doi.org\/10.1056\/NEJMoa2025797","journal-title":"N Engl J Med"},{"key":"10497_CR125","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","volume":"139","author":"DA Morrow","year":"2019","unstructured":"Morrow DA, Velazquez EJ, DeVore AD et al (2019) Clinical outcomes in patients with acute decompensated heart failure randomly Assigned to Sacubitril\/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation 139:2285\u20132288. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039331","journal-title":"Circulation"},{"key":"10497_CR126","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"44","author":"J Biegus","year":"2023","unstructured":"Biegus J, Voors AA, Collins SP et al (2023) Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J 44:41\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehac530","journal-title":"Eur Heart J"},{"key":"10497_CR127","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ejhf.2206","volume":"23","author":"GMC Rosano","year":"2021","unstructured":"Rosano GMC, Moura B, Metra M et al (2021) Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 23:872\u2013881. https:\/\/doi.org\/10.1002\/ejhf.2206","journal-title":"Eur J Heart Fail"},{"key":"10497_CR128","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","volume":"20","author":"J Com\u00edn-Colet","year":"2018","unstructured":"Com\u00edn-Colet J, Manito N, Segovia-Cubero J et al (2018) Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail 20:1128\u20131136. https:\/\/doi.org\/10.1002\/ejhf.1145","journal-title":"Eur J Heart Fail"},{"key":"10497_CR129","doi-asserted-by":"publisher","first-page":"C15","DOI":"10.1093\/eurheartj\/sux003","volume":"19","author":"MS Nieminen","year":"2017","unstructured":"Nieminen MS, Fonseca C, Brito D, Wikstr\u00f6m G (2017) The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure. Eur Hear J Suppl 19:C15\u2013C21. https:\/\/doi.org\/10.1093\/eurheartj\/sux003","journal-title":"Eur Hear J Suppl"},{"key":"10497_CR130","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone GW, Lindenfeld J, Abraham WT et al (2018) Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379:2307\u20132318. https:\/\/doi.org\/10.1056\/NEJMoa1806640","journal-title":"N Engl J Med"},{"key":"10497_CR131","doi-asserted-by":"publisher","unstructured":"Breitenstein A, Steffel J (2019) Devices in Heart Failure Patients\u2014Who Benefits From ICD and CRT? Front Cardiovasc Med 6. https:\/\/doi.org\/10.3389\/fcvm.2019.00111","DOI":"10.3389\/fcvm.2019.00111"},{"key":"10497_CR132","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jchf.2021.12.002","volume":"10","author":"BD Atwater","year":"2022","unstructured":"Atwater BD, Yousuf OK (2022) ICD Versus CRT-D Implantation. JACC Hear Fail 10:158\u2013160. https:\/\/doi.org\/10.1016\/j.jchf.2021.12.002","journal-title":"JACC Hear Fail"}],"updated-by":[{"DOI":"10.1007\/s10741-025-10507-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000}}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10497-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10497-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10497-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:40:27Z","timestamp":1749800427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10497-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":132,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["10497"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10497-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10741-025-10507-0","asserted-by":"object"}]},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"11 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to present the correct first and last names of the authors.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10741-025-10507-0","URL":"https:\/\/doi.org\/10.1007\/s10741-025-10507-0","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"CF received consultancy fees, grants, and speaker\u2019s honoraria from Astra Zeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, and CSLVifor. RB received speaker, advisory board, and grant funding fees from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Lilly, Menarini, Merck, MSD, Novartis, Pfizer, Servier Portugal, and Vifor Pharma. FF received consultant fees from Bayer, AstraZeneca, Boehringer Ingelheim, and Medinfar. BM received consultant or speaking fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Servier, Novartis, Vifor pharma, and Viatris. JP received speaker and consultant fees from Astra Zeneca, Bayer, Bial, Boehringer-Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche diagnostics, Servier, and CSL Vifor. PMS received consultant or speaking fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Pfizer. JSC received research, consultant, or speaking fees from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Eli Lilly, Novartis, Pfizer, Servier, and Vifor Pharma. DB received consultancy fees and lectures or scientific meeting sponsorship from Alnylam, AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}